Research Article
High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform
Table 2
HIFU surgery and perioperative details.
| | Parameters | With fusion | Without fusion | Overall | value |
| | Mean total operative time (mins) ± SD | 124.2 ± 16.9 | 107.1 ± 28.3 | 115.2 ± 24.6 | 0.066 | | Mean actual HIFU time (s) ± SD | 37.4 ± 10.9 | 42.9 ± 13.2 | 40.3 ± 12.2 | 0.172 | | HIFU with urethral catheter in situ (n) | 4 | 3 | 7 (35%) | 0.639 | | Lesion visible on ultrasound during HIFU (n) | 5 | 6 | 11 (55%) | 0.653 | | Number of ablation zones used during HIFU | | | | | | 1 (n) | 0 | 0 | 0 (0%) | | | 2 (n) | 0 | 5 | 5 (25%) | | | 3 (n) | 10 | 5 | 15 (75%) | | | Mean ablation volume to lesion volume ratio | 62.8 | 66.4 | 65.1 | 0.473 | | Mean urethral catheter in situ days ± SD | 8.7 ± 7.2 | 9.8 ± 5.7 | 9.3 ± 6.4 | 0.355 | | Same day discharge from the hospital (n) | 8 | 3 | 11 | 0.025 | | 90-day complication (Clavien-Dindo grade) (n) | | | | | | Grade 1 | 1 | 3 | 4 | 0.264 | | Grades 2–5 | 0 | 0 | 0 | | | Mean PSA percentage change from baseline to 6-month (%) ± SD | 44.6 ± 21.0 | 63.3 ± 22.4 | 53.9 ± 23.2 | 0.035 |
|
|
PSA, prostate-specific antigen; SD, standard deviation.
|
